<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <title>Exonsi Therapeutics</title>
  <style>
    body {
      font-family: Arial, sans-serif;
      margin: 0;
      line-height: 1.6;
      background: #f9f9f9;
      color: #333;
    }
    header {
      background: #003366;
      color: #fff;
      padding: 2rem;
      text-align: center;
    }
    section {
      padding: 2rem;
      max-width: 900px;
      margin: auto;
    }
    h2 {
      color: #003366;
    }
    footer {
      background: #003366;
      color: #fff;
      text-align: center;
      padding: 1rem;
      margin-top: 3rem;
    }
    .team {
      display: flex;
      gap: 1rem;
      flex-wrap: wrap;
    }
    .team-member {
      flex: 1 1 250px;
      background: #fff;
      padding: 1rem;
      border-radius: 8px;
      box-shadow: 0 0 5px rgba(0,0,0,0.1);
    }
  </style>
</head>
<body>

<header>
  <h1>Exonsi Therapeutics</h1>
  <p>Targeted, Non-Invasive Glioblastoma Solutions</p>
</header>

<section>
  <h2>The Problem</h2>
  <p>Glioblastoma is one of the most aggressive forms of brain cancer. With a five-year survival rate of just 6.9% and an average life expectancy of 8 months post-diagnosis, patients need better solutions. Current treatments are invasive, risky, and often ineffective.</p>
</section>

<section>
  <h2>Our Solution</h2>
  <p>We are developing a revolutionary blood test that detects glioblastoma early using cfDNA methylation analysis. Our long-term solution is a proprietary exosome-based treatment that targets the tumor while preserving healthy brain tissue—offering safe, effective, and repeatable care.</p>
</section>

<section>
  <h2>Technology</h2>
  <ul>
    <li>Cell-free DNA (cfDNA) analysis for early detection</li>
    <li>Home or clinic-based blood collection options</li>
    <li>Exosome delivery using stem cells, T cells, or siRNA</li>
    <li>Future plans: CRISPR-loaded exosomes for gene editing</li>
  </ul>
</section>

<section>
  <h2>Our Team</h2>
  <div class="team">
    <div class="team-member">
      <h3>Ian Jones</h3>
      <p>Chief Executive Officer (CEO)</p>
    </div>
    <div class="team-member">
      <h3>Shaheer Paracha</h3>
      <p>Chief Technology Officer (CTO)</p>
    </div>
    <div class="team-member">
      <h3>Nathan Stinnett</h3>
      <p>Chief Financial Officer (CFO)</p>
    </div>
  </div>
</section>

<section>
  <h2>Vision & Investment</h2>
  <p>We are seeking a $7.5 million investment for R&D, testing kits, exosome research, and customer discovery. Our company projects entry into human trials within 5–7 years, with long-term profitability and sustainable subscription models for ongoing treatment.</p>
</section>

<section>
  <h2>Contact Us</h2>
  <p>Interested in learning more or investing?</p>
  <p>Email: <a href="mailto:exonsi@therapeutics.com">exonsi@therapeutics.com</a></p>
</section>

<footer>
  &copy; 2025 Exonsi Therapeutics. All rights reserved.
</footer>

</body>
</html>
